TOBIN JAMES R
Known title: DirectorCIK: 0001190128
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
TransMedics Group Faces Analyst Sentiment Shift. Barclays has begun covering TransMedics Group, giving it an overweight rating and a $120 price target. At the same time, Intel downgraded the company while Marvell upgraded it, showing mixed analyst views. These moves may influence how investors view the stock, especially as it trades near its 52‑week range. The company remains in a neutral technical zone with an RSI of 45 and support at $74.62.
Transaction History
| GMED | ▲ Buy | Option Exercise | 15,000 | $806K | 9/15/2026 | View on chart |
| GMED | ▲ Buy | Option Exercise | 15,000 | $955K | 9/15/2026 | View on chart |
| GMED | ▼ Sell | Open Market | 30,000 | $2.2M | 9/15/2026 | View on chart |
| TMDX | ▼ Sell | Gift | 18,000 | $0 | 8/17/2026 | View on chart |
| TMDX | ▲ Buy | Grant | 2,922 | $0 | 5/20/2026 | View on chart |
| TMDX | ▲ Buy | Grant | 2,134 | $0 | 5/22/2025 | View on chart |
| TMDX | ▼ Sell | Gift | 18,000 | $0 | 9/13/2024 | View on chart |
| TMDX | ▼ Sell | Gift | 18,000 | $0 | 9/13/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 7,336 | $1.2M | 8/8/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 12,664 | $2.0M | 8/8/2024 | View on chart |
| TMDX | ▲ Buy | Grant | 732 | $0 | 5/23/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 6,895 | $864K | 5/3/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 5,130 | $640K | 5/3/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 1,704 | $182K | 5/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 2,000 | $220K | 5/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 11,236 | $1.2M | 5/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 100 | $11K | 5/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 2,900 | $246K | 3/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 300 | $26K | 3/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 200 | $16K | 3/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 4,234 | $351K | 3/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 5,746 | $481K | 3/1/2024 | View on chart |
| TMDX | ▼ Sell | Open Market | 10,000 | $701K | 11/28/2023 | View on chart |
| TMDX | ▲ Buy | Grant | 1,193 | $0 | 5/25/2023 | View on chart |
| TMDX | ▼ Sell | Open Market | 10,000 | $751K | 2/23/2023 | View on chart |
| TMDX | ▼ Sell | Open Market | 48,515 | $1.9M | 7/29/2022 | View on chart |
| TMDX | ▼ Sell | Open Market | 48,515 | $1.7M | 7/5/2022 | View on chart |
| TMDX | ▼ Sell | Open Market | 48,516 | $1.5M | 5/4/2022 | View on chart |
| GMED | ▲ Buy | Option Exercise | 3,542 | $189K | 3/15/2022 | View on chart |
| GMED | ▲ Buy | Option Exercise | 5,308 | $231K | 3/15/2022 | View on chart |
| GMED | ▼ Sell | Open Market | 8,850 | $579K | 3/15/2022 | View on chart |
| GMED | ▲ Buy | Option Exercise | 10,000 | $436K | 3/10/2022 | View on chart |
| GMED | ▼ Sell | Open Market | 10,000 | $700K | 3/10/2022 | View on chart |
| GMED | ▲ Buy | Option Exercise | 4,484 | $195K | 3/8/2022 | View on chart |
| GMED | ▼ Sell | Open Market | 4,484 | $323K | 3/8/2022 | View on chart |
| TMDX | ▼ Sell | Gift | 25,500 | $0 | 12/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85
RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.